Inclusion Criteria:

          1. Patient has a histologically or cytologically confirmed diagnosis of non-small cell
             lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by
             the FDA approved Abbott FISH Test.

          2. Patient has stage IIIB or IV diagnosis and must have received one or two prior
             regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of
             locally advanced or metastatic NSCLC.

          3. Patient has at least one measurable lesion as defined by RECIST 1.1. A previously
             irradiated site lesion may only be counted as a target lesion if there is clear sign
             of progression since the irradiation

          4. Patients must have received previous treatment with crizotinib for the treatment of
             locally advanced or metastatic NSCLC.

        Exclusion Criteria:

          1. Patient with known hypersensitivity to any of the excipients of LDK378
             (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
             magnesium stearate)

          2. Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel
             or any known excipients of these drugs.

          3. Patient with symptomatic central nervous system (CNS) metastases who is neurologically
             unstable or has required increasing doses of steroids within the 2 weeks prior to
             screening to manage CNS symptoms.